OI Ljubljana
Sl

Institute of Oncology

Sectors

For Patients

Programs and Projects supported by the Slovenian Research and Innovation Agency

The majority of researches carried out at the Institute are supported financially by the Slovenian Research and Innovation Agency (SRIA). Comprehensive studies are carried out within research programs and targeted studies within research projects.

Research programs

CodeProgramme titlePeriodPrincipal Investigator at the Insitute of Oncology
P3-0003 Development and evaluation of new approaches to cancer treatment 1. 7. 2004 – 31. 12. 2027Acad. Prof. Serša Gregor
P3-0289 Characteristics of malignant neoplasms important for diagnosis, prognosis and treatment outcome 1. 7. 2004 - 31. 12. 2027Prof. Nikola Besic PhD
P3-0307 Cancer of the head and neck - analysis of biological characteristics and an attempt to improve treatment results 1. 1. 2019-31. 12. 2027Prof. Primoz Strojan PhD
P3-0321 Prognostic and predictive factors for response in treatment of different types of cancer 1. 1. 2020-31. 12. 2027Prof. Janja Ocvirk
P3-0352 (C) Moderate and high cancer risk population: counseling, mutational screening and prevention strategies 1. 1. 2009-31. 12. 2027Prof. Janez Zgajnar PhD
P1-0389 Medical physics 1. 1. 2015-31. 12. 2027Assist. Bozidar Casar, BSc
P3-0428-0428 Comparative oncology for tackling rare cancers 1. 1. 2022-31. 12. 2027Prof. Ario de Marco, Prof. Maja Cemazar
P3-0429 Slovenian research programme for comprehensive cancer control SLORApro 1. 1. 2022 - 31. 12. 2027 Prof. Vesna Zadnik

Research projects

CodeProject titlePeriodPrincipal Investigator at the Insitute of Oncology
N1-0197 Improving breast cancer screening through dynamic big data analytics of Quantitative Imaging Biomarkers 1. 1. 2021-31. 12. 2024Assoc. Prof. Robert Jeraj /Mateja Krajc
Z3-1873 A novel vascular targeted approach based on gene therapy silencing two independent signaling pathways in combination with radiotherapy 1.7.2019 - 30.6.2022dr. Monika Savarin
V3-2236 Assessment of the potential impact of incineration and co-incineration of waste on human health effects: a model study on the case of the Salonit Anhovo cement plant 1. 10. 2022-30. 12. 2024Vesna Zadnik, PhD
V3-2239 Needs assessment, identification of criteria and development of a model for the organization of palliative cancer care at the national level 1. 10. 2022-1. 10. 2025Vesna Zadnik, PhD
V3-2241 Pilot research on individualized comprehensive rehabilitation of patients with colorectal cancer 2022-2024 1. 10. 2022-30. 9. 2024Assoc. Prof. Nada Rotovnik Kozjek
V3-2320 Pilot implementation REsearch for revision of screening policy in the NatiOnal cerVicAl cancer screening program ZORA (PRENOVA ZORA) 1.10. 2023-30. 09. 2026 Assoc. Prof. Urška Ivanuš
V3-2321 Framework development for evidence-based, sustainable implementation of organised population-based lung cancer screening in Slovenia (LUKA) 1. 10. 2023 – 30. 9. 2025assist. prof. Martina Vrankar, PhD
V3-2326 Preparation of epidemiological bases fort he introduction of new national cancer screening program in Slovenia 1. 10. 2023–30. 9. 2025Tina Žagar, PhD
V5-24042 KrizKom: Crisis communication in cases of public health crises and active listening 1. 10. 2024 – 30. 9. 2026Dejan Verčič, PhD, Prof.
J3-3083 Vascularization and vascular effects as predictive factors for local ablative techniques 1.9.2021 - 30.9.2025acad. prof. dr. Serša Gregor
J3-3084 Inducible programming of CAR T cell intrinsic properties for cancer immunotherapy 1.9.2021 - 31.8.2024dr. Anže Smole (National Institute of Biology) / prof. dr. Maja Čemažar (Institute of Oncology Ljubljana)
J1-4417 Development of novel small molecule Toll-like receptors 7 and 8 modulators for cancer immunotherapy 1. 10. 2022 - 30. 9. 2025Prof. Matej Sova PhD
J7-4491 Development of integrated multi-channel artificial nose for detection of cancer 1. 10. 2022 - 30. 9. 2025Prof. Igor Muševič PhD
J3-4504 Uncovering the glioblastoma microenvironment to enhance the therapy 1. 10. 2022 - 30. 9. 2025Metka Novak, PhD
J7-4540 Socio-economic consequences of cancer from the perspective of the individual and society including the impact of COVID-19 pandemic 1. 10. 2022 - 30. 9. 2025Asst Prof. Ivica Ratosa
J7-4635 MitoCan - Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy 1. 10. 2022 - 30. 9. 2025Prof. Lucija Peterlin Masic PhD
J2-50068 Safety and efficacy of high frequency electrochemotherapy - clinical device development 1. 10. 2023-30. 09. 2026 Asst. Prof. Matej Reberšek
J3-50108 DEBIO 1143 has a potential to increase effectiveness of electrochemotherapy and radiotherapy in HPV positive and HPV negative Head and Neck Cancers 1. 10. 2023 – 30. 9. 2026Katarina Žnidar, PhD
J3-50110 Intratumoral mRNA electrotransfer: establishment and preclinical proof of concept 1. 10. 2023–30. 9. 2026Katja Uršič Valentinuzzi, PhD
L3-50111 Gene immune-therapy of solid tumors based on mRNA encoding interleukin-12: So-rlL 1. 10. 2023 – 30. 9. 2026Prof. Maja Čemažar, PhD
Z3-50112 Irradioation and learned immunity: The role of NK cells 1. 10. 2023–30. 9. 2025Tim Božič, PhD
J7-50128 TRACE METALS DISORDER AS BIOMARKER IN BILIARY TRACT CANCERS 1. 10. 2023-30. 9. 2026 Asst. Prof. Janez Ščančar
J4-50150 Erythrocyte membrane-based nanocarriers for gene silencing cancer therapy 1. 10. 2023 – 30. 9. 2026Boštjan Markelc, PhD
J3-60068 Circulating tumor cell translational research platform 1. 1. 2025 – 31. 12. 2027Tanja Jesenko, PhD, Prof.

Research infrastructure

CodeProgramme titlePeriodPrincipal Investigator at the Insitute of Oncology
I0-0059 Infrastructure activity/group 1. 1. 2022–31. 12. 2027Bostjan Markelc, PhD

Completed research projects

CodeProject titlePeriodPrincipal Investigator at the Insitute of Oncology
COST- Cancer and Work Network (CANWON): ISCH COST Action IS1211 Assoc. Prof. Vesna Zadnik PhD
- Implementation of the clinical pathway for dietary treatment of hospitalized patients, screening tools for dietary treatment of outpatients and guidelines for the physical activity of patients 2017-2019Nada Rotovnik Kozjek
- Cancer incidence at dravsko polje: geographical analysis of cancer incidence in the municipality of Rače-Fram and surrounding settlements 2018 - 2019Prof Vesna Zadnik PhD
N3-0059 Plasma-assisted wound treatment and topical introduction of molecules 1.1.2017 - 31.12.2020dr. Uroš Cvelbar (Jozef Stefan Institute)/acad. prof. dr. Serša Gregor (Institute of Oncology Ljubljana)
IP-0302 Lifelong Follow-Up of Survivors of Childhood and Adolescent Cancer and Related Translational Trials 1. 1. 2009-31. 12. 2021Asst. Prof. Lorna Zadravec Zaletel PhD
V3-1638 (C) Development and implementation of personalised breast cancer risk evaluation tool for Slovenian population 1. 10. 2016-30. 9. 2019Assoc. Prof. Vesna Zadnik PhD
V3-1713 (B) Comprehensive analysis of management of urological cancer patients with an assessment of possible delays in referrals, realization of diagnostics procedures and first treatment 1.4.2018 - 31.03.2020Assoc. Prof. Vesna Zadnik PhD
V3-1718 Health risk assessment for exposures of children to low-frequency electric and magnetic (EM) fields in Slovenia 1.4.2018 - 31.3.2021Prof. Tadej Kotnik PhD, Prof. Vesna Zadnik PhD
V3-1720 (B) Analysis and estimation of requirements of human resources for cancer treatment in Slovenia 1.4.2018 - 31.3.2020Prof. Branko Zakotnik PhD
J2-1732 Computer-assisted medical image analysis for proton and radiotherapy treatment planning 1. 7. 2019 - 30. 6. 2022Prof. Tomaž Vrtovec
J3-1753 Molecular predictors of radiation treatment response in breast cancer 1. 7. 2019-30. 6. 2022Asst. Prof. Katja Goricar, Asst. Prof. Tanja Marinko
J3-1760 The role of imaging and laboratory markers in the evaluation of nature and growth of thyroid nodules 1. 7. 2019-30. 6. 2022Prof. Katja Zaletel / Prof. Nikola Besic
BI-AT-18-19-003 Cancer stem cell (CSC)-associated exosomes as regulators of tumor radiation response 1.1.2018 - 31.12.2019prof. dr. Maja Čemažar
Z3-1871 Combination of electrochemotherapy with poly (adenosin diphosphate-ribose) polymerase inhibitor in treatment of breast cancer 1.7.2019 - 30.6.2021dr. Maša Bošnjak
V3-1906 Pilot study on individualized integrated rehabilitation of breast cancer patients 2019-2022 1. 11. 2019-30. 4. 2023Prof. Nikola Besic
V3-1907 Development of indicators and methodology for monitoring the late effects of cancer treatment in childhood at national level 1. 11. 2019-31. 10. 2021Assoc. Prof. Vesna Zadnik
V3-1911 Slovenian genome project 1. 11. 2019 – 31. 10. 2022Assoc. Prof. Borut Peterlin
V3-2032 The impact of COVID-19 on the cancer management in Slovenia 1. 10. 2020-30. 9. 2022Tina Žagar PhD
BI-US-22-24-026 Factors affecting combined electrochemotherapy with immunogene therapy of cancer 1. 7. 2022-30. 6. 2024Acad. Prof. Serša Gregor
BI-US-22-24-070 Bridging the gap between three-dimensional biomimetic vascular models and in vivo tumor vasculature 1. 7. 2022-30. 6. 2024dr. Boštjan Markelc
J3-2524 Minimally invasive diagnostic approaches in brain tumours using circulating cell-free nucleic acids 1. 9. 2020-31. 8. 2023Assoc. Prof. Jože Pižem
J3-2527 New approaches for prediction of cardiotoxicity in breast cancer radiotherapy 1. 9. 2020-31. 8. 2023Assist. Prof. Tanja Marinko
J3-2528 Immuno gene electrotransfer of IL-12 and IL-2 in immunologically cold/hot tumors 1.9.2020 - 31.8.2023prof. dr. Maja Čemažar
J3-2529 Role of endothelium in tumor response to radiotherapy 1.9.2020 - 31.8.2023dr. Boštjan Markelc
J3-2537 New method for estimating life-years gained in population-based cancer screening programmes (S-LYG) 1.9.2020-31.8.2024Prof. Vesna Zadnik PhD
J4-2546 Monitoring of the clinical and immune response to improve the outcome of combined electrochemotherapy and IL-12 gene therapy in dogs with spontaneous peripheral tumours 1.9.2020 - 31.8.2023prof. dr. Nataša Tozon (Veterinary Faculty)/prof. dr. Maja Čemažar (Institute of Oncology Ljubljana)
J4-2594 The amniotic membrane as a novel multimodal therapy for bacterial cystitis and bladder cancer: unravelling its antimicrobial, immunomodulatory and anticancer activity 1.9.2020 - 31.8.2023prof. dr. Mateja Erdani Kreft (Faculty of Medicine)/ prof. dr. Maja Čemažar (Institute of Oncology Ljubljana)
L3-2622 Biological markers of development, progression and treatment response in asbestos related diseases 1. 9. 2020-31. 8. 2023Assoc. Prof. Vita Dolžan, Prof. Viljem Kovac
Z3-2651 Electrochemotherapy as in situ vaccination therapy 1. 9. 2020 - 31. 8. 2023dr. Katja Uršič Valentinuzzi
J2-3059 Online adaptive re-planning in proton and radiotherapy 1. 10. 2021-30. 9. 2024prof. Žiga Špiclin and prof. Primoz Strojan
J3-3062 Autologous immunohybridomas and advanced treatment of stage II and III triple-negative breast cancer 1. 10. 2021 - 30. 9. 2024Prof. Matjaž Jeras, Assist. Simona Borstnar
J3-7272 (A) Methods of estimation of key indicators in population cancer survival 1.1.2016 - 31.12.2018prof. dr. Pohar Perme Maja (Univerza v Ljubljani, Medicinska fakulteta), prof. dr. Vesna Zadnik (Onkološki inštitut)
J3-7372 Molecular biomarkers and biomarker-driven therapy in lung cancer 2016-2018Prof. Tanja Čufer, Assoc. Prof. Viljem Kovač
J3-7460 Irradiation dose modifying factor of squamous cell carcinoma of the oropharynx infected by human papillomavirus: an in vitro and in vivo study in laboratory mouse tumor model 1.1.2016 - 31.12.2018prof. dr. Strojan Primož/Institute of Oncology Ljubljana
J3-7494 Tunneling nanotubes for innovative urinary bladder cancer treatment 2016-2018Prof. Maja Cemazar PhD
L2-7550 Electrospun nanofibrous materials for solid state drug delivery system 1.3.2016 - 28.2.2019prof. dr. Igor Emri /acad. prof. dr. Gregor Serša (Institute of Oncology Ljubljana)
J1-8140 Endocrine disrupting and genotoxic potential of protein kinase inhibitors: relevance for environmental hazard 1.5.2017 - 30.4.2021prof. dr. Filipič Metka (National Institute of Biology) / prof. dr. Maja Čemažar (Institute of Oncology Ljubljana)
J3-8202 Time-lapse intra-vital imaging of immune response after electrochemotherapy induced in situ vaccination and interleukin-12 gene therapy boost 1.5.2017 - 30.4.2021prof. dr. Maja Čemažar
L3-8203 Serum, genetic and epigenetic markers of risk for developing, progress and treatment response in asbestos related diseases 1. 5. 2017-30. 6. 2020Assoc. Prof. Viljem Kovač
Z3-8204 Involvement of cytosolic DNA sensors in irradiation induced bystander and abscopal effect 1.4.2018 - 31.3.2020dr. Tanja Jesenko
J3-8210 Potential of low, sub-therapeutic doses of statins and sartans in primary and secondary cardiovascular disease prevention 2017-2020Sr. Res. Fell. Srdjan Novaković
J4-8227 Cathepsin X inhibitors impair the resistence of tumor cells to antiprotease therapy 1.5.2017 - 30.4.2020prof. dr. Kos Janko (Univerza v Ljubljani, Fakulteta za farmacijo/IJS)/ acad. prof. dr. Gregor Serša (Onkološki inštitut)
J2-9225 Non-invasive technique for Cell Membrane Permeabilization using pulsed electromagnetic fields 1.7.2018 - 30.6.2021prof. dr. Damijan Miklavčič (Faculty of Electrical Engineering/ acad. prof. dr. Gregor Serša Institute of Oncology Ljubljana
J3-9269 Clinical pharmacological approach to optimization of therapeutic concentration of bleomycin treatment with electrochemotherapy 1.7.2018 - 30.6.2021acad. prof. dr. Serša Gregor
J5-9336 Opportunities and dangers of online health communities for healthcare 2018-2022Asst. Prof. Rok Petrič

 

 

Institute of Oncology Ljubljana

Zaloška cesta 2
1000 Ljubljana
T: +386 1 5879 110
F: +386 1 5879 400
E: info@onko-i.si

Sectors

For Patients

© 2019 - Institute of Oncology Ljubljana
 Legal Notifications / RSS
Authors
Accessibility(CTRL+F2)
color contrast
text size
highlighting content
zoom in
accessibility statement report an accessibility problem